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Background: CD100, also known as Sema4D, is an immune semaphorin constitutively expressed on natural killer (NK) cells and T cells. As an immune activation molecule, CD100 has important immunoregulatory effects on NK functions by enhancing
the interactions between NK cells and target cells. The aim of this study was to
investigate whether hepatitis C virus (HCV) infection affects CD100 expression, and
whether interferon-α treatment enhances NK killing activity to facilitate HCV clearance
via CD100.
Methods: Expression of CD100 on NK cells was evaluated by flow cytometry in patients
with chronic HCV infection, with or without pegylated interferon-α-based therapy. NK cell
cytotoxicity and interferon (IFN)-γ production were measured by flow cytometry upon
culturing the NK cells with K562 and Huh7.5 or HCV JFH-1-infected Huh7.5 cells.
Results: The frequency of CD100+ NK cells in HCV-infected individuals was slightly
suppressed compared to healthy subjects. IFN-α treatment could significantly upregulate CD100 expression, which was confirmed by in vitro studies using peripheral blood
mononuclear cells cocultured with HCV-expressing Huh7.5 cells or IFN-α. Importantly,
the expression of CD100 on NK cells from HCV patients was inversely associated with
the HCV-RNA levels in the early phase of IFN-α therapy, and the IFN-α upregulated
CD100 led to an enhanced NK killing activity through ligations with its receptors plexin-B1/B2 on target cells.
Conclusion: These results implied a novel mechanism by which IFN-α enhanced
CD100/Plexin-B1/B2 interaction plays an important role in promoting NK functions in
patients with chronic hepatitis C.
Keywords: hepatitis C virus, natural killer cells, interferon-α, CD100, plexin-B1/B2
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INTRODUCTION

that IFN-α-enhanced CD100 expression may represent a novel
mechanism involved in antiviral immune responses.

Hepatitis C virus (HCV) is a blood-borne pathogen, leading to
severe liver diseases in millions of people worldwide (1). Immune
responses play a crucial role in infection control and disease
progression (2). Natural killer (NK) cells, an important innate
immune cell population, provide early defense against viral
infections by killing infected cells and producing cytokines, such
as interferon (IFN)-γ, that inhibit viral replication (3). Recently,
several studies have shown that NK cells are involved in antiHCV immune responses in both acute and chronic HCV infection (4–9). Despite controversy regarding NK cell phenotype and
function (8–12), NK cells are known to be functionally impaired
during HCV infection (13, 14); the underlying mechanisms,
however, have not been well defined.
While the current therapy for chronic hepatitis C involves
direct-acting antiviral (DAA) agents, pegylated interferon (PegIFN)-α therapy provides a specific model for immune regulation
during antiviral treatment (15). Therefore, it is important to
understand the mechanisms of IFN-α-mediated HCV clearance.
In addition to a direct antiviral activity (16), IFN-α likely exerts
immunomodulatory effects on eliminating HCV-infected hepatocytes (17). Several studies have revealed that IFN-α-induced
tumor necrosis factor-related apoptosis inducing ligand (TRAIL)
and degranulation by NK cells play important roles in killing
virus-infected cells (4, 8, 17). However, the potential molecular
mechanisms underlying IFN-α-mediated anti-HCV immune
responses remain elusive.
Semaphorins were originally identified as axon guidance
factors involved in the development of the neuronal system.
Sema4D, also known as CD100, was the first immune semaphorin
discovered and is constitutively expressed on resting T cells and
NK cells (18). CD72, plexin-B1, and plexin-B2 serve as the CD100
receptors in the immune system (19–21). Accumulating evidence
indicates that CD100 plays an essential role in immune regulation
by enhancing effector functions (20, 22–28).
Natural killer cell activation is primarily regulated by integration of signals from a diverse array of activating and inhibitory
receptors (29, 30). The recognition and interactions between
effectors and their targets exert essential effects on killing virusinfected cells. It has been reported that CD100, as an immune
activation molecule, is involved in the NK killing process through
signal activation between NK cells and target cells by binding to
CD72 (31). Recently, Eriksson et al. have revealed that CD8+
T cells lacking CD100 expression are increased and functionally
impaired during HIV infection (28), suggesting that viral infection
might also have an impact on CD100 expression and its functions.
In the study, we examined CD100 expression on NK cells from
chronically HCV-infected patients with or without IFN-α therapy,
including those with sustained virological response (SVR), and
early virological response (EVR). The effects of CD100 on NK cell
functions were also examined. For the first time, we demonstrate
that CD100 expression is suppressed on NK cells in patients with
chronic HCV infection, and IFN-α therapy can enhance CD100/
plexin-B1/B2 interactions between NK cells and HCV-infected
hepatocytes, leading to a more efficient killing activity and
enhanced IFN-γ production by NK cells. These results suggest
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MATERIALS AND METHODS
Subjects

This study includes the following subjects (as summarized in
Table S1 in Supplementary Material): (i) 30 treatment-naive
patients with chronic hepatitis C. All patients tested positive for
anti-HCV with a third-generation enzyme-linked immunosorbent assay (Kechuang and Xinhua, Shanghai, China). HCV RNA
levels were quantified using a reverse transcription polymerase
chain reaction (RT-PCR) assay (Qiagen, Shenzhen, China), with
a lower limit of detection for 100 copies/ml. All patients were
negative for antibodies against hepatitis B, hepatitis D, and human
immunodeficiency virus; (ii) 25 HCV patients who achieved an
EVR (defined as serum HCV RNA being undetectable, <100 copies/ml), at week 12 after initiation of Peg-IFN-α-2a (180 μg/week
subcutaneously) and weight-based ribavirin (800–1,200 mg,
depending on the HCV genotype); (iii) 20 HCV patients who
achieved an SVR (defined as HCV RNA remains undetectable
for at least 6 months after treatment discontinuation) following
Peg-IFN-α and ribavirin therapy; (iv) 24 age- and sex-matched
healthy volunteers. Informed consent was obtained from all participating subjects. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki and was approved
by the Research and Ethical Committee of Tangdu Hospital of the
Fourth Military Medical University.

Cell Isolation and Purification

Peripheral blood mononuclear cells (PBMCs) were freshly isolated from peripheral blood by density gradient centrifugation
using Ficoll-Hypaque (Sigma, St. Louis, MO, USA) and frozen
or immediately studied as described below. If indicated, NK cells
were further purified from PBMCs by negative selection using a
human NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. The
purity of NK cells was measured by flow cytometry after staining the cells with anti-CD3-Cy5.5/PerCP (Clone: UCHT1, BD
Biosciences, San Jose, CA, USA) and anti-CD56-Pe-Cy7 (Clone:
B159, BD Biosciences, San Jose, CA, USA), with the frequency of
CD3−CD56+ cells above 90% and CD3+ cells less than 1% to be
used for subsequent experiments.

HCVcc Generation and Infection

Hepatitis C virus JFH-1 (genotype 2a) was produced as described
previously (32). The JFH-1 expression construct (kindly provided
by Dr. C. Rice, Rockefeller University, New York, NY, USA) was
linearized, and full-length JFH-1 RNA was transcribed using
a MEGAscript T7 in vitro transcription kit (Ambion, Austin,
TX, USA) per manufacturer’s instructions. 5 × 105 Huh7.5 cells
(kindly provided by Dr. C. Rice) were transfected at 70–80%
confluent in a six-well plate with 2 µg transcribed RNA using
DMRIE-C reagent per company’s protocol (Invitrogen, Carlsbad,
CA, USA). HCV antigen expression was examined at 48 h after
transfection by immunofluorescence using HCV NS5 antibodies
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(ViroGen, Watertown, MA, USA) and the supernatant collected
from HCV RNA-transfected Huh7.5 cells at 48 h was used to
infect naive Huh7.5 cells to make HCV stocks. HCV titer was
detected as previously described (33).
Peripheral blood mononuclear cells (0.5 × 106 cells) from
healthy subjects were infected by coculture with JFH-1/Huh7.5
cells at an effector-to-target (E:T) ratio of 10:1 or with HCV particles at a multiplicity of infection (MOI) of 10 for 48 h. Complete
cell culture medium was used as negative control. After incubation, cells were stained for anti-CD3 (Clone: UCHT1), CD14
(Clone: M5E2), CD19 (Clone: HIB19), CD56 (Clone: B159),
CD16 (Clone: 3G8), all from BD Biosciences, San Jose, CA, USA,
and CD100 (Clone: A8, BioLegend, San Diego, CA, USA) monoclonal antibodies followed by flow cytometric analysis.

USA) and monensin (0.67 µl/ml) (BD Biosciences, San Jose, CA,
USA) were added for another 4 h prior to harvesting the cells.
Finally, NK cells were washed, stained with anti-CD3, CD16,
CD56, and CD100, and analyzed by flow cytometry.

RNA Extraction and Quantification

RNA was extracted using the RNeasy mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Quantification of messenger RNA (mRNA) levels of plexin-B1
and plexin-B2 were performed by real-time PCR. GAPDH served
as the internal control. Primer sequences used for real-time PCR
analysis were listed in Table S2 in Supplementary Material.

Statistical Analysis

Statistical analyses were performed with GraphPad Prism Version
5.0 (GraphPad Software Inc., San Diego, CA, USA). The Shapiro–
Wilk test was used to test the normal distribution of quantitative
variables. When quantitative variables were normally distributed,
the results were presented as mean ± SD, otherwise median and
interquartile range (25th–75th percentile) were reported; differences between two or three groups were evaluated by parametric
or non-parametric tests according to data distribution. Paired
Student’s t-test was used to assess paired variables. Correlations
between variables were evaluated with the Spearman rank correlation test. p < 0.05 was considered as statistically significant.

IFN-α Treatment

We also observed the effect of IFN-α on CD100 and plexin-B1/B2
expression. PBMCs (0.5 × 106 cells) were incubated in 1 ml complete medium supplemented with IFN-α-2a (at a concentration
ranging from 0.01 to 1,000 ng/ml) (Roche Bioscience, Hillview
Avenue Palo Alto, CA, USA) in a 24-well round-bottom plate
(Corning, One Riverfront Plaza, NY, USA.) for 2, 6, 12, 24, and
48 h, respectively, and Huh7.5 cells were stimulated with IFNα-2a (10 ng/ml) for 48 h. Complete cell culture medium was used
as controls. After incubation, cells were stained with monoclonal
antibodies as described above for flow cytometric analysis.

RESULTS

NK Cell Phenotypic and Functional
Characterization

Phenotypic Change of NK Cells from
Chronic HCV Infection

For phenotypic analysis, PBMCs isolated from HCV patients and
healthy subjects were stained with CD3-Cy5.5/PerCP (Clone:
UCHT1), CD14-Cy5.5/PerCP (Clone: M5E2), CD19-Cy5.5/
PerCP (Clone: HIB19), CD16-Cy7/APC (Clone: 3G8), CD56PeCy7 (Clone: B159), CD69-FITC (Clone: FN50), TRAIL-PE
(Clone: S35-934), all from BD Biosciences, San Jose, CA, USA,
CD100-FITC (Clone: A8, BioLegend, San Diego, CA, USA) or
isotype matched controls (BD Biosciences, San Jose, CA, USA).
Plexin-B1/B2 expression on K562 (ATCC, Manassas, VA, USA)
and Huh7.5 cells (used as target cells) were measured using
RT-PCR (primers were listed in Table S2 in Supplementary
Material) and flow cytometry with plexin B1 and plexin B2 antibody (Clone: #559830&#537223, R&D Systems Inc., Minneapolis,
MN, USA). Immunostained cells were analyzed on a multicolor
Arial II (BD Biosciences, San Jose, CA, USA) and FlowJo Version
7.6.2 software.
For analysis of cytokine production and degranulation, purified NK cells were resuspended at 105 cells/ml and stimulated with
either (i) K562, Huh7.5 or JFH-1/Huh7.5 cells at an E:T ratio of
1:1; (ii) K562, Huh7.5 or JFH-1/Huh7.5 cells at an E:T ratio of 1:1
in the presence of IFN-α (10 ng/ml); (iii) K562, Huh7.5 or JFH-1/
Huh7.5 cells preincubated for 2 h with soluble CD100 (sCD100)
(PeproTech, Rocky Hill, NJ, USA) or antiplexin B1/2 antibodies
mix (Clone: sc28372&sc373969, Santa Cruz, CA, USA) to block
availability of plexin-B1/B2; (iv) complete cell culture medium
without target cells and cytokines as control. After 8 h incubation
at 37°C, Brefeldin A (10 ng/ml) (eBioscience, San Diego, CA,
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Based on CD56 and CD16 expression, NK cells can be divided
into CD56bright (CD56++CD16±) and CD56dim (CD56+CD16+)
subsets (34). CD3/14/19−CD56+ NK cells and their CD56bright and
CD56dim subsets were identified in PBMCs using multicolor flow
cytometry by immune-staining for CD3, CD14, CD19, CD56,
and CD16 (Figure 1A). To identify the specific effect of HCV
infection on NK cells, we conducted an ex vivo cross-sectional
analysis to investigate the CD100, CD69, and TRAIL expression
on NK cells from HCV patients versus healthy subjects. As shown
in Figure 1B, the percentage of CD100+ NK cells was slightly
decreased in patients with chronic HCV infection compared to
healthy subjects, though this did not achieve a significant difference. Similarly, no significant changes were observed in the
frequency of CD69+ NK and TRAIL+ NK cells between HCV
patients and healthy subjects, though these phenotypic markers
were slightly upregulated in the setting of HCV infection. These
data suggest that NK cells were not successfully activated during
chronic HCV infection.
To investigate whether CD100 was implicated in liver injury
and disease progression, we observed the correlation between
the measured molecules with ALT and HCV-RNA levels. We
found that CD100+ NK as well as TRAIL+ NK cells positively
correlated with the serum ALT levels, but inversely correlated
with the HCV-RNA titers (Figures 1C,D). Moreover, the level
of CD100 was found to be related to the TRAIL expression on
CD56bright NK cells (Figure 1E); however, no correlations were

3

November 2017 | Volume 8 | Article 1435

He et al.

CD100 Signaling Enhances NK Function

Figure 1 | Natural killer (NK) cell phenotypic analysis in patients with chronic hepatitis C virus (HCV) infection. 99 subjects were recruited in the studies, including
24 healthy subjects, 30 HCV patients, 25 early virological response (EVR) patients, and 20 sustained virological response (SVR) patients. All HCV patients were
treated with pegylated interferon (Peg-IFN)-α and RBV therapy. (A) Gating strategy. (B) Frequency of CD100, CD69, and TRAIL expression on total NK and two
subsets in patients with chronic HCV infection (HCV, filled circles) and healthy subjects (HC, open circles). (C,D) Correlation analysis between CD100 or TRAIL
expression on NK cells and ALT levels or HCV-RNA titer. (E) The relationship between CD100 and TRAIL in CD56bright NK cells. The Mann–Whitney U test was used
for the statistical analysis.

found between the CD69 expression on NK cells and the ALT or
HCV-RNA levels.

TRAIL expressions by NK cells before and after IFN-α treatment in chronically HCV-infected patients who achieved EVR
and SVR, respectively. We found that the proportion of CD100+,
CD69+ and TRAIL+ NK cells was significantly upregulated in
patients with EVR, and returned to normal in patients with
SVR after IFN-α treatment (Figure 2A). Of note, the expression of CD100 was increased in both CD56bright and CD56dim NK
subsets, whereas CD69 expression mainly increased in CD56dim

IFN-α Significantly Upregulated CD100
Expression on NK Cells

To determine whether IFN-α can activate NK cells in vivo and
upregulate CD100 expression, we examined CD100, CD69 and

Frontiers in Immunology | www.frontiersin.org
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NKs, and TRAIL expression primarily increased in CD56bright
NK subsets, respectively (Figure 2A). Furthermore, we also
examined the relationship between CD100 or TRAIL expression and HCV RNA titer in 6 patients at the very early phase of
Peg-IFN-α and ribavirin treatment. PBMCs from these patients
were collected on days 0 and 7 of treatment, and HCV-RNA in
serum was quantified. At day 0 of treatment, about 74.3% of
CD56bright NKs and 52.1% of CD56dim NKs were CD100+ cells.
After 7 days of treatment, however, the percentage of CD100+
CD56bright NKs and CD100+ CD56dim NKs increased to 89.1 and
74.5%, respectively. Similarly, TRAIL+ cells were also increased
from 22.1 to 58.7% in CD56bright NK subset (Figure 2B).
Importantly, the upregulation of CD100 on both NK subsets
and TRAIL on CD56bright NK cells were inversely correlated
with the HCV-RNA decline during the early phase of antiviral
treatment (Figure 2C). These results indicated that IFN-α treatment efficiently activated NK cells, and the increased CD100
and TRAIL expressions on NK cells correlated with the HCV
control.

enhance CD100 and plexin-B1/B2 expressions on NK cells,
which may influence signal transduction between NK cells and
target cells.

IFN-α Enhanced NK Cell Degranulation
and IFN-γ Production

Natural killer cell activation typically results in cytotoxicity/
degranulation and release of antiviral cytokines, including IFN-γ.
Several lines of evidence have shown that NK cells from HCVinfected patients display a functional dichotomy, characterized by
normal or enhanced cytotoxicity and reduced production of IFNγ (8–10, 35, 36). To investigate whether HCV and IFN-α could
affect NK cell killing activity to target cells in the in vitro system, we
cocultured purified NK cells with K562, Huh7.5 or HCV JFH-1infected Huh7.5 (JFH-1/Huh7.5) cells in the presence or absence
of IFN-α. As shown in Figure S1C in Supplementary Material,
HCV had a strong effect on CD107a expression, especially on
CD56dim subsets, but not on IFN-γ production (Figure S1D in
Supplementary Material). In response to K562 cells, IFN-α treatment effectively activated NK cells through increased degranulation on both NK subsets and enhanced IFN-γ production on
CD56dim NK subset (Figures 4A,B). Correspondingly, similar
results were observed (increased CD107 and IFN-γ expression
in NK cells, particularly in CD56dim subsets) upon coculturing
NK cells with Huh7.5 (Figures 4C,D) or JFH-1/Huh7.5 cells
(Figures 4E,F).

IFN-α Increased CD100 and Plexin-B1/B2
Expressions In Vitro

To further elucidate the role of HCV in regulation of CD100
expression and to mimic the in vivo setting of HCV infection,
we employed a cell coculture system by incubating healthy
PBMCs with Huh7.5 hepatocytes transfected with HCV JFH-1
strain in vitro. NS5 protein was detected in HCV-JFH-1 transfected Huh7.5 cells by immunofluorescent staining (Figure S1A
in Supplementary Material). Additionally, Huh7.5 cells can
be infected by the supernatant of JFH-1-transfected Huh7.5
cells (Figure S1B in Supplementary Material), suggesting that
HCV particles are secreted from the HCV mRNA-transfected
hepatocytes into the culture media. We incubated healthy
PBMCs with medium alone vs. medium containing HCV
virions (MOI = 10) or Huh7.5 vs. JFH-1-infected Huh7.5 cells
for 48 h, followed by immune-staining and flow cytometric
analysis. As shown in Figure 3A, CD100 expression on NK cells
was not affected by the HCV particles; but it was remarkably
decreased on PBMCs cocultured with JFH-1-infected Huh7.5
compared with those incubated with Huh7.5 cells without HCV
infection (Figure 3B).
Next, we examined the effect of IFN-α on CD100 expression
on NK cells, and found that CD100+ NK cells were significantly
upregulated, in a dose- and time-dependent manner, in PBMCs
stimulated with IFN-α (Figure 3C). CD100 expression began
to rise at 6 h and peaked at 12 h following IFN-α treatment. As
shown in Figure 3D, the same effect was observed in different
NK subsets in PBMCs derived different donors incubated with
IFN-α for 12 h. We also examined whether IFN-α can affect the
expression of CD100 receptors, plexin-B1/B2, on Huh7.5 cells.
Indeed, plexin-B1 and plexin-B2 expressions were upregulated
by IFN-α, which reached a maximum effect at 24 h, following
IFN-α treatment (Figures 3E,F). The CD72, another important
CD100 receptor, was checked as well. However, it cannot be
detected on Huh7.5 cells or HCV-infected/IFN-α treated
Huh7.5 cells. These results indicated that IFN-α treatment can

Frontiers in Immunology | www.frontiersin.org

CD100/Plexin-B Interactions Involved in
NK Functions in Response to Target Cells

Previous studies have reported that degranulation and IFN-γ
production of NK cells could be induced via activation of the
IFN-α/β receptor (37, 38), it was not clear however whether other
molecules were involved in this process, especially in response
to target cells. To explore the mechanisms underlying NK cell
functions in response to target cells, we studied the potential
involvement of IFN-α, CD100, and plexin-B1/B2 in NK degranulation and IFN-γ production. Since we have shown that IFN-α
is involved in NK regulation, we hypothesized that CD100 and
plexin-B1/B2 interactions have functional consequences on the
NK killing process. To test this hypothesis, we blocked the availability of plexin-B1/B2 by preincubating sCD100 with K562 cells.
As shown in Figure 5A, the optimal blockade was observed at a
concentration of 50 ng/ml, with a plateau being observed thereafter. Interestingly, it was found that the expression of CD107a on
NK cells declined, whereas CD100 expression upregulated with
increasing the sCD100 concentrations. This phenomenon might
imply a negative loop between CD100–plexin-B interaction and
CD100 expression. CD100–plexin B ligation could trigger Erk
signaling within the cells (20). Thus, we believe that the ligations of CD100–plexin-B downregulate CD100 expression on
NK cells through the MAPK signal transduction, whereas the
interaction blockage by sCD100 rescues CD100 expression in
NK cells. The plexin B1/2 antibodies were also used for CD100/
plexin B interaction blockade according to previous studies (39).
As expected, CD107a expression decreased in total NK as well as
in the two NK subsets, particularly in the presence IFN-α after
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Figure 2 | Alteration of natural killer (NK) cell phenotype in hepatitis C virus (HCV) patients after initiating antiviral treatment. (A) The percentage of CD100, CD69,
and TRAIL expression on total NK and subsets in treatment-naive patients with chronic hepatitis C (circles), patients with early virological response (EVR, triangles)
and sustained virological response (SVR, squares) after IFN-α-based therapy. (B) Representative staining of CD100 and TRAIL in one patient with the frequency of
CD100 and TRAIL expressing CD56bright and CD56dim NK cells. (C) CD100 and TRAIL expression on CD56bright (filled circles) and CD56dim NK cells (open circles) and
HCV-RNA titer (filled rhombus). *p < 0.05, **p < 0.01, ***p < 0.001. Dunn’s Multiple Comparison was used for comparison between the two groups. Kruskal–Wallis
H was employed for comparison more than three groups. HCV patients were treated with Peg-IFN-α (180 μg/injection) and RBV (1,200 mg/d for genotype 1b;
900 mg/d for genotypes 2 and 3).

blocking plexin-B1/B2 availability by sCD100 or plexin B1/2
antibodies (Figure 5B); this was also true for IFN-γ production
(Figure 5C). Taken together, these results revealed an important
role of CD100–plexin-B1/B2 interactions in NK degranulation
and IFN-γ production in response to target cells.

Frontiers in Immunology | www.frontiersin.org

DISCUSSION
Many molecules are involved in the complex immune response
that occurs during HCV infection and antiviral treatment. Our
findings in this study suggest that HCV infection and IFN-α
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Figure 3 | Interferon (IFN)-α increases CD100 and plexin-B1/B2 expression in vitro. (A,B) Peripheral blood mononuclear cells (PBMCs) cocultured with medium
alone vs. medium containing hepatitis C virus (HCV) virions [multiplicity of infection (MOI) = 10]. (C,D) PBMCs cocultured with Huh7.5 cells vs. JFH-1/Huh7.5 cells.
Huh7.5 cells were infected by the supernatant of HCV JFH-1-transfected Huh7.5 cells at 48 h, E:T = 10:1. (E,F) Plexin-B1 and plexin-B2 was upregulated by IFN-α
(10 ng/mL) and the effect reached its maximum at 24 h after IFN-α treatment. *p < 0.05, **p < 0.01, ***p < 0.001. Paired Student’s t-test was used for the data
analysis.

treatment affect the expressions of CD100 and its receptors,
plexin-B1/B2. IFN-α further upregulates CD107a and IFN-γ
expression in NK cells in response to target cells. Based on the
novel finding of CD100 changes in HCV patients before and after
antiviral treatment, we believe that the CD100–plexin-B1/B2
interactions play an important role in NK cell killing activity in
response to HCV infection. We thus propose a model that in the
HCV-infected liver, NK cells recognize HCV-infected hepatocytes
via CD100–plexin-B1/B2 interactions so as to facilitate NK killing activities. IFN-α-based therapy not only efficiently activates
NK cells, but improves the interactions between NK effectors
and HCV-infected cells via increases in CD100 and plexin-B1/
B2 expressions (Figure 6).

Frontiers in Immunology | www.frontiersin.org

Natural killer cell activity is regulated through three major
mechanisms: first, the balance between inhibitory and activating
receptors on NK cell surface; second, the cross-talk with other
cells, especially with dendritic cells (40, 41); and third, NK cell
recognition and interaction with virus-infected cells (31, 42).
Here, we demonstrate that HCV infection does not completely
activate NK cells; i.e., the expressions of CD100, the early activation marker CD69, and the apoptotic molecule TRAIL in our
HCV cohort are found at similar levels to those observed in
healthy subjects. Earlier reports revealed that NK cell activity was
compromised after exposure to HCV virions or HCV-infected
hepatocytes (13, 14, 32, 43, 44). Consistent with two of these
studies (32, 43), CD100 expression on NK cells is decreased after

7

November 2017 | Volume 8 | Article 1435

He et al.

CD100 Signaling Enhances NK Function

Figure 4 | The effect of interferon (IFN)-α on CD107a and IFN-γ expressions by natural killer (NK) cells in response to target cells in vitro. Peripheral blood
mononuclear cells (PBMCs) were incubated with medium containing hepatitis C virus (HCV) at multiplicity of infection (MOI) of 10 or Huh7.5 cells or JFH-1/Huh7.5
cells, with or without IFN-α treatment, in the presence of K562 target cells for 48 h, respectively. Huh7.5 cells were infected by the supernatant of HCV JFH-1transfected Huh7.5 cells at 48 h, E:T = 10:1. (A,C,E) CD107a expression and (B,D,F) IFN-γ expression on total NK and NK subsets was measured by flow
cytometry. *p < 0.05, **p < 0.01, ***p < 0.001. Paired Student’s t-test was used for the data analysis.

Frontiers in Immunology | www.frontiersin.org

8

November 2017 | Volume 8 | Article 1435

He et al.

CD100 Signaling Enhances NK Function

Figure 5 | CD100–plexin-B1/B2 interactions involved in natural killer (NK) cell killing process. CD100–plexin-B1/B2 interactions were blocked by sCD100 or plexin
B1/B2 antibodies preincubating. (A) Dose-dependent effect of sCD100 on the expressions of CD107a and CD100 on NK cells in the context of interferon (IFN)-α
treatment. (B,C) CD107a and IFN-γ expressions in total NK and the two subsets, in the presence or absence of IFN-α, sCD100, or plexin B1/2 antibodies.
*p < 0.05, **p < 0.01, ***p < 0.001. Paired Student’s t-test was used for the data analysis.

exposure to JFH-1/Huh7.5 cells, but not to HCV particles in our
in vitro experiments.
Partially in line with other reports (4, 8, 17, 36), we demonstrate that IFN-α significantly upregulates the expression level
of CD100, CD69, and TRAIL in chronic HCV patients after
initiation of antiviral treatment, and this is also supported by
our in vitro IFN-α stimulation assays. Furthermore, CD100 and
TRAIL expression on NK cells appears to correlate with HCV
clearance. To mimic the in vivo setting, we used PBMCs derived

Frontiers in Immunology | www.frontiersin.org

from HCV patients to examine CD100 expression on NK cells by
IFN-α stimulation. Notably, CD100 can regulate many immune
responses through CD72- or plexin B-induced downstream
signal activation; however, the upstream elements of CD100
regulation remain unclear. Based our previous results, IFN-α
positively regulates CD100 expression. And it is likely through
control of JAK-STAT signal transduction (45, 46). On the other
hand, our results demonstrate that HCV infection suppresses
CD100 expression on NK cells. In conjunction with HCV’s
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Figure 6 | CD100–plexin-B1/B2 interactions facilitate immune responses of natural killer (NK) cells. We propose a model that NK cells recognize hepatitis C virus
(HCV)-infected hepatocytes via CD100–plexin-B1/B2 interactions and facilitate the NK killing activity in HCV infection. Interferon (IFN)-α-based therapy not only
efficiently activates NK cells, but improves the activation between NK effectors and HCV-infected cells via increased CD100 and plexin-B1/B2 expressions.

suppressive effects on JAK-STAT signaling (47, 48), these data
indirectly support the notion that the JAK-STAT pathway may
interface with CD100 expression on NK cells.
Based on the correlation analysis, we speculate that CD100
and TRAIL might be associated with immune-mediated hepatic
inflammation and elimination of HCV infection. Moreover,
CD100 expression is related to TRAIL expression in CD56bright
NK cells, further suggesting that CD100 is associated with TRAILmediated apoptosis of HCV-infected cells. Interestingly, while
the level of CD100 is related to TRAIL expression on CD56bright
NK cells, it is not on CD56dim NK cells. CD100 exerts different
effect on CD56bright and CD56dim NK subsets, implying different
signal transductions exist between the NK subsets. As such,
alteration of expression of CD100 and its receptors plexin-B1/
B2 could be a potential antiviral mechanism for IFN-α treatment.

Frontiers in Immunology | www.frontiersin.org

Several studies have demonstrated that IFN-α treatment markedly increases CD107a expression and decreases IFN-γ production
(4, 6, 8, 9, 36), and work by Szabo indicates that IFN-γ production
is increased after exposure to exogenous IFN-α (41). As with these
investigations, we also employed HCV-infected Huh7.5 as target
cells to investigate variations in NK functions. Previous studies
have reported that CD100, which is significantly upregulated after
cellular activation (21, 26, 49), and has an immunomodulatory
effect on both humoral and cellular immune responses (18, 20,
22, 25, 27, 50). Recently, Eriksson et al demonstrated that CD100
is also involved in T cell responses during HIV infection (28).
However, it is still unclear whether chronic HCV infection affects
CD100 expression on NK cells and related immune responses.
We reveal a novel mechanism in which NK cell degranulation
and IFN-γ production are enhanced through CD100–plexin-B1/
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